Overview
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma
Status:
Recruiting
Recruiting
Trial end date:
2023-06-30
2023-06-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Weill Medical College of Cornell UniversityCollaborator:
William Rhodes Center for GlioblastomaTreatments:
Alovudine
Criteria
Inclusion Criteria:- Male or female ≥ 18 years of age
- Documentation of a suspected HGG diagnosis based on clinical and MRI findings
Exclusion Criteria:
- Pregnant or breastfeeding
- Contraindications to receiving Positron Emission Tomography (PET) imaging (e.g.
claustrophobia)